Fri, Aug 29, 2014, 6:03 AM EDT - U.S. Markets open in 3 hrs 27 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • downbythewater@ymail.com downbythewater Mar 3, 2013 4:21 PM Flag

    New antibiotics not delivery systems get GAIN status Trius developing antibiotics for the future

    Last month Trius received the QIDP designation(created by the Generating Antibiotic Incentives Now (GAIN) Act,because Trius's development of new antibiotics.
    Insmed is on a completely different path and does not qualify for GAIN
    Trius Phase3 results initiated the ruling because of the inovation of the antibiotic
    Insmed will grind along thru the regulatory process.NTM is in phase2B.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • downbythewater@ymail.com downbythewater Mar 3, 2013 4:25 PM Flag

      ,,since I am invested in Trius(&Insmed) who is dealing with antibiotics is that there is a rising resistance to antibiotics, mostly coming out of China. There are no new antibiotics. More advanced antibiotic companies are creating antibiotics a different way - eliminating an enzyme that the bacteria needs to sustain and grow or they die. The bacteria is not attacked and thus can't mutate. Therefore no resistance. This is the future of antibiotics

      • 3 Replies to downbythewater
      • downbythewater@ymail.com downbythewater Apr 14, 2013 1:15 PM Flag

        ,,since I am invested in Trius(&Insmed) who is dealing with antibiotics is that there is a rising resistance to antibiotics, mostly coming out of China. There are no new antibiotics. More advanced antibiotic companies are creating antibiotics a different way - eliminating an enzyme that the bacteria needs to sustain and grow or they die. The bacteria is not attacked and thus can't mutate. Therefore no resistance. This is the future of antibiotics

      • by rehdvm2004•

        All antibiotics interfere with some physiological function of bacteria. The antibiotics that kill or cause stasis (non-growth) of Gram negatives invariably damage the bacterial organelles or block metabolism. The ones that kill Gram positives interfere with the cell wall (different from a bacterial cell membrane) or get into the cell and damage physiological function. There there are the highly resistant NTM, TB and fungi. These bacteria/fungi have cell walls that are extremely resistant. Arikace works against NTM because it is concentrated inside the cells (fixed macrophages) that take in but cannot kill the NTM by the normal process. By taking in Arikace, the antibiotic is concentrated in the same microenvironment as the NTM bringing the antibiotic (amikacin) to toxic levels for the bacteria. This will probably not work for TB (and INSM is not suggesting any different) because the bacterial cell wall of TB is enriched with three types of mycolic acids that make the bacteria impenetrable by normal antibiotics. The drugs used to treat TB attack the outer acid fast cell wall of the TB. The only more resistant cell wall microbes are fungi which actually are single cell plants. They have a carbon fiber cell walls of chitin (same as crab shells) and polysccharides (insoluble sugars). That is why there are so many antibiotics and so many arrays of treatment. No one antibiotic treats all which is a blow to the Spumpers on this MB

      • All antibiotics interfere with some physiological function of bacteria. The antibiotics that kill or cause stasis (non-growth) of Gram negatives invariably damage the bacterial organelles or block metabolism. The ones that kill Gram positives interfere with the cell wall (different from a bacterial cell membrane) or get into the cell and damage physiological function. There there are the highly resistant NTM, TB and fungi. These bacteria/fungi have cell walls that are extremely resistant. Arikace works against NTM because it is concentrated inside the cells (fixed macrophages) that take in but cannot kill the NTM by the normal process. By taking in Arikace, the antibiotic is concentrated in the same microenvironment as the NTM bringing the antibiotic (amikacin) to toxic levels for the bacteria. This will probably not work for TB (and INSM is not suggesting any different) because the bacterial cell wall of TB is enriched with three types of mycolic acids that make the bacteria impenetrable by normal antibiotics. The drugs used to treat TB attack the outer acid fast cell wall of the TB. The only more resistant cell wall microbes are fungi which actually are single cell plants. They have a carbon fiber cell walls of chitin (same as crab shells) and polysccharides (insoluble sugars). That is why there are so many antibiotics and so many arrays of treatment. No one antibiotic treats all which is a blow to the Spumpers on this MB.

        Sentiment: Strong Buy

 
INSM
13.82-0.12(-0.86%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Williams-Sonoma Inc.
NYSEThu, Aug 28, 2014 4:02 PM EDT
Veeva Systems Inc.
NYSEThu, Aug 28, 2014 4:01 PM EDT